For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA StudyFellström B.a · Holdaas H.b · Jardine A.G.c · Rose H.d · Schmieder R.e · Wilpshaar W.f · Zannad F.g
aDepartment of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden; bDepartment of Nephrology, Rikshospitalet, University of Oslo, Oslo, Norway; cBHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow; dAstraZeneca, Macclesfield, UK; eDepartment of Nephrology and Hypertension, Universitätsklinik, Erlangen-Nürnberg, Erlangen, Germany; fformer AstraZeneca, Macclesfield, UK and gClinical Investigation Centre INSERM (CIC), Hôpital Jeanne d’Arc, Toul, France Corresponding Author
Professor Bengt Fellström
Department of Medical Science, Renal Unit, University Hospital
SE–751 85 Uppsala (Sweden)
Tel. +46 18 611 0000, ext. 4348, Fax +46 18 38304
Background: Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Aims: AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) is the first large-scale international trial to assess the effects of statins on cardiovascular outcomes in patients with ESRD on chronic haemodialysis. Preliminary baseline data from the randomised population are presented. Methods: A total of 2,775 patients from 280 centres in 25 countries were randomised into the study. Patients aged 50–80 years on regular chronic haemodialysis for at least 3 months before screening were eligible for inclusion. They were randomised 1:1 to receive either rosuvastatin 10 mg or placebo daily and assessed throughout the study. Results: The mean age at baseline was 64 years. Most patients were male (62%) and 85% were white. The median time since commencing renal replacement was 32 months. Mean total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were 4.53 mmol/l (175 mg/dl) and 2.57 mmol/l (99 mg/dl), respectively. Conclusion: Results from the AURORA trial will impact on the current guidelines and use of statins in this patient population.
© 2007 S. Karger AG, Basel